LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression

Abstract EN

Drug resistance to platinum limited therapeutic options for oral squamous cell carcinoma (OSCC).

In the current study, we investigated the role of lncRNA HOMEOBOX A11 (HOXA11) antisense RNA (HOXA11-AS) in OSCC resistance to cisplatin (CDDP).

We used clinical tissues and OSCC cell lines and induced CDDP resistance in OSCC cells.

Gain and loss of function were performed in OSCC-resistant cells.

Xenograft mice were also established.

HOXA11-AS expression was increased in OSCC clinical tissues and cell lines and upregulated in CDDP-resistant cells.

Upregulation of HOXA11-AS promoted proliferation in CDDP-sensitive cells and inhibited CDDP-induced cytotoxicity.

In contrast, downregulation of HOXA11-AS decreased proliferation in CDDP-resistant cells and increased CDDP-induced cytotoxicity.

Knockdown of HOXA11-AS inhibited the tumor growth in xenograft mice injected by CDDP.

Downregulation of HOXA11-AS increased apoptosis and caspase 3 activities in CDDP-resistant OSCC cells.

Bioinformatics, reporter assay, and loss and gain of function assay indicated that HOXA11-AS and miR-214-3p could negatively regulate each other.

miR-214-3p was decreased in OSCC clinical tissues and cell lines.

We further revealed that proto-oncogene serine/threonine-protein kinase (PIM1) was the target of miR-214-3p.

PIM1 expression could be negatively regulated by miR-214-3p and positively regulated by HOXA11-AS.

Inhibition of PIM1 suppressed anti-miR-214-3p-induced increase of cell proliferation and decrease of apoptosis.

In summary, HOXA11-AS was identified to facilitate CDDP-resistance in OSCC and miR-214-3p/PIM1 was found to be the downstream target of HOXA11-AS.

The findings highlight the importance of HOXA11-AS/miR-214-3p/PIM1 axis in the drug resistance of OSCC and provide potential targets for improving chemotherapy of OSCC.